Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

2016/09/07 by Christoph Höner zu Siederdissen, Franziska Rinker, Benjamin Maasoumy +12 · 27 citations
Medicine · #Hepatitis B Virus Studies #Hepatitis C virus research #Liver Disease Diagnosis and Treatment

paper · pdf · doi:10.1093/infdis/jiw412

Abstract

This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.

Cited by

• Hepatitis B – Ein Ausblick auf aktualisierte Leitlinien
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
• The Role of cccDNA in HBV Maintenance. [europepmc]
• Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. [europepmc]
• Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. [europepmc]
• On the future of therapeutic vaccination in chronic hepatitis B. [europepmc]
• Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. [europepmc]
• Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. [europepmc]
• cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. [europepmc]
• D e novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. [europepmc]
• Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. [europepmc]
• HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. [europepmc]
• Discontinuation of antiviral therapy in chronic hepatitis B patients. [europepmc]
• The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. [europepmc]
• Challenges in the discontinuation of chronic hepatitis B antiviral agents. [europepmc]
• Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. [europepmc]
• Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. [europepmc]
• Current Trend in Antiviral Therapy for Chronic Hepatitis B. [europepmc]
• Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. [europepmc]
• Hepatitis B Virus Reactivation Increased the Risk of Developing Hepatic Failure and Mortality in Cirrhosis With Acute Exacerbation. [europepmc]
• Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. [europepmc]
• Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. [europepmc]
• Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines. [europepmc]
• Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. [europepmc]
• Results of Nucleos(t)ide Analog Treatment Discontinuation in Hepatitis B e-Antigen-Negative Chronic Hepatitis B: NUCSTOP Study. [europepmc]
• [The partial cure represents an intermediate endpoint on the path to a functional cure, not an ideal endpoint]. [europepmc]
• The effect of treatment cessation on HBsAg negativity in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)id analogues for more than three years. [europepmc]

Related

• Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study
• Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
• Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen–Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study
• Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study
• Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation